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the cost of treatment with Peg-Interferon Alpha-2a is lower compared to Peg-In-
terferon Alpha 2b. For a 10-year projection which simulates through a Markov
model that patients that did not respond to treatment evolved to chronicity of the
disease costs per patient with Peg-interferon Alpha-2a was $ 25,913, while with
Peg-Interferon Alpha-2b was $ 37,352, generating savings of $ 11,439 per patient
who was treated with Peg-interferon Alpha-2a. CONCLUSIONS: The use of Peg-
Interferon Alpha-2a was the dominant alternative because it was the most effec-
tive and least costly to treat HCV.
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OBJECTIVES: TNF antagonists are effective therapy for moderate to severe active
Crohn’s disease (CD). Despite their efficacy, these monoclonal antibodies are asso-
ciated with high treatment costs. The objective was to evaluate the economic
impact of the introduction of anti-TNFs for CD treatment on health care resource
utilization fromahealth care systemperspective.METHODS:A retrospective study
was conducted using a random sample of patients diagnosed with CD (ICD-
9555.x) who initiated adalimumab or infliximab therapy between January 2001
and December 2009. Prescription and medical data from the Régie de l’assurance-
maladie du Québec were also obtained from three samples of age- and gender-
matched controls: 1) general population; 2) CD patients treated neither with anti-
TNFs nor antimetabolites; and 3) CD patients taking only antimetabolites. Health
care resource utilization and costs were estimated for the year preceding and fol-
lowing index date. Disease severity was assessed through prednisone and antime-
tabolite use and healthcare resource utilization in the year before index date.
RESULTS: A cohort of 614 patients was obtained (mean age40.5years, 61% fe-
males). Anti-TNF treated patients’ average cost for health care resources was
CAN$7,202. In comparison, costs in the general population, patients treated neither
with anti-TNFs nor antimetabolites, and patients taking only antimetabolites,were
CAN$1,093, CAN$2,029, and CAN$3,024 respectively. In the year before anti-TNF
initiation, CD patients received more prednisone and antimetabolites and used
more health care resources. Following anti-TNF initiation, the cost of drugs re-
ceived was higher for this cohort, but costs of medical visits, ER visits and hospi-
talizations were significantly lower (CAN$882 vs. CAN$554, CAN$297 vs. CAN$161,
and CAN$5,423 vs. CAN$2,963, respectively, p0.001 for all). CONCLUSIONS: Bio-
logic users are more likely to have severe CD than controls resulting in higher
medical resource consumption and greater prednisone and antimetabolites use.
Initiation of a biologic treatment in these patients is associated with lower health
care resource utilization and cost offsets.
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OBJECTIVES: Several studies show that adherence is an important factor to treat-
ment success, improving patient outcomes and reducing global costs. The aim of
this study is to estimate the clinical and economic impact of non-adherence by
patients with ulcerative colitis in remission that are undermaintenance treatment
with mesalazine in the Brazilian Public Healthcare perspective. METHODS: We
compared two schemes of Mesalazine 2 grams/per day: once daily (2 grams sachet)
or twice daily (two 500 mg capsules q12). We constructed a decision tree analytical
model to compare costs and outcomes of Mesalazine once daily (MOD) with Me-
salazine twice daily (MTD) over 12 months. Treatment pathways described in the
model are based on Brazilian Government Clinic and Therapeutics Guidelines,
therefore, biological drugs were not considered in this analysis, because there are
not reimbursed. In both arms, the failure to maintain remission led to other treat-
ments, as needed: prednisone, cyclosporin, azatioprine and colectomy. Adherence
data was obtained from real life prospective studies (Kane et. al.). Costs considered
were: drug, laboratory and diagnostic tests’ costs, specialist consultation and hos-
pitalization costs (all costs are referred to year 2011). The mains outcomes consid-
ered were colectomy surgery avoided and rates of remission without relapse.
RESULTS: Results of the analysis suggest that the average aggregated treatment
cost per person for all medical interventions at 12 months was lower for MOD
compared with MTD (USD 1924 versus USD 1957). Additionally, there is a trend
towards improved effectiveness with MOD inmaintenance remission of ulcerative
colitis with 6.6% re-inductions and 17.2% colectomy surgeries avoided.
CONCLUSIONS: Results from base-case and sensitivity analysis indicate that MOD
presents lower costs and better effectiveness than MTD from a public payers’ per-
spective in Brazil.
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OBJECTIVES: To compare the all-causemedical resource utilization in chronic liver
disease (CLD) patients with thrombocytopenia (TCP) versus no thrombocytopenia,
using the Veterans health administration (VHA) database. METHODS: All utiliza-
tion records of patients in the VA national patient care databases, who had a
diagnosis of CLD between 1999 and 2008, were followed from the date of CLD
diagnosis to 180 days following the earlier of two events: the last date a platelet
count was available for each patient, or the date of the last platelet count of fewer
than 50,000 cells / L. Platelet counts and outcomes such as, number of physician
visits (PV) and outpatient procedures (OPP), and healthcare costs (HCC) were deter-
mined for every threemonth period up to study end for each eligible patient, using
a longitudinal per patient per 3-month dataset. Generalized linear models (GLMs)
were used to study the impact of change in platelet counts on health care utiliza-
tion and costs, after adjusting for hepatitis C infection and other covariates.
RESULTS: A total of 935 and 256,516 patient-3-month observations were available
for comparing health care use in CLD patientswith TCP versus no TCP respectively.
After adjusting for liver disease severity and other covariates incidence rate ratios
for PV and OPP for an increase in platelet counts by 25,000, were 0.992 (95% CI:
0.990-0.993, p 0.0001) and 0.989 (95% CI: 0.987 – 0.990, p 0.0001) respectively. For
a decrease in platelet counts of 10,000 and 25,000 among observations with a max-
imum platelet count of 50,000 / L during the study period, the average predicted
change in overall health care costs per quarterwas$139 (SD: $379) and$369 (SD:
$1,004), respectively (p  0.0001). CONCLUSIONS: In a VA patient population with
CLD, TCP is associated with modest increase in health care utilization and costs as
compared to no TCP.
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OBJECTIVES: Patients with chronic constipation (CC) are often treated with diverse
over the counter (OTC) laxatives, bulking agents, stool softeners, and a limited
choice of prescription (Rx) drugs. Sub-optimal treatment often results in adverse
medical events or treatmentmodifications. The purpose of this study is to estimate
healthcare resource utilization (HRU) and costs of such unmet treatment needs.
METHODS: Data from the Missouri Medicaid program covering medical services
and Rx andOTCmedications (1997-2010) were used to select adult patientswith CC
receiving constipation treatments. The index date was defined as the date of the
first constipation-treatment claim. Indicators of unmet treatment needs were ob-
served during the one-year period after the index date and defined as the following
events occurring while on constipation treatment: 1) switch to or addition of a new
constipation treatment; 2) constipation-related inpatient (IP) or emergency room
(ER) admission; 3) megacolon or fecal impaction diagnosis; 4) constipation-related
surgery/medical procedure; or 5) use of other unusual constipation treatments.
Incremental HRU and costs (USD 2010; measured from a public-payer perspective)
were compared between patients with and without indicators of unmet needs
using multivariate generalized linear regression models. RESULTS: A total of 8745
patients with CC were identified; 54.9% of them were found to have unmet needs
during the one-year period following the index date. After adjusting for baseline
differences, indicators of unmet needs were associated with more HRU, especially
the number of IP days (IRR 1.54; P0.001) and ER admissions (IRR1.35; P0.001).
Indicators of unmet needs were associated with a $2,978 incremental total annual
healthcare costs (P0.001) compared to patients without indicators of unmet
needs. The cost difference was mainly driven by IP ($2,575 vs. $1,534; P0.001) and
pharmacy ($7,114 vs. $5,929; P0.001) costs. CONCLUSIONS: Unmet treatment
needs among CC patients were associated with a significant economic burden.
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OBJECTIVES: Previous studies demonstrate that diverticulitis (DV) is costly to pay-
ers. Most research focuses on total costs and acute episodes, while the burden of
recurrent episodes is not well documented. This study assessed the direct eco-
nomic burden associated with DV recurrence among managed care enrollees.
METHODS: Data were drawn from insurance claims from 40 US health plans.
Patients with a primary DV diagnosis (ICD-9-CM 562.11 or 562.13) between January
1, 2005 to December 31, 2008 were subjected to the following criteria: antibiotic
treatment 3 days post-diagnosis and 6 months continuous pre- and 12
months post-index date (first observed DV diagnosis) plan enrollment. The first 6
weeks post-index date defined the initial acute episode period. Within a given
6-week period following the acute episode, a recurrent episode was defined by a
DV-related hospitalization or ER visit, or a DV-related office visit with antibiotic
treatment within 3 days of the visit. Those with a recurrence were stratified into
those with and without surgical intervention. Recurrence-related costs (2009 US$)
were evaluated for 12 months post-initial acute episode. RESULTS: A totall 36,636
patients were selected (53% male, mean age 52 years); 16.5% (N6,045) had 1
recurrence. Among those with 1 recurrence, the mean number (SD) of recur-
rences was 1.3 (0.6), while the total cost of all recurrences was 4 times the initial
acute episode cost ($12,806 vs. $3,132). For the surgical group (N2868), the differ-
ence between the total cost of all recurrences and initial acute episode costwas still
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4 times ($24,247 vs. $6,903). For the non-surgical group (N3177), however, the
total cost of all recurrences was slightly less than initial acute episode costs ($2478
vs. $2648). CONCLUSIONS: Costs associated with recurrent DV episodes are signif-
icant, with recurrences costing substantially more than initial acute episodes.
Among those with a recurrence, significant variation in costs among those with
and without surgical intervention exists.
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OBJECTIVES: Little is known about the overall burden of chronic hepatic diseases
(CHDs) for the health care third-payer, patients and their families. We performed a
Cost of Illness study named COME, to assess the societal burden (direct, indirect
and intangible costs) in patients with CHDs. The following results pertain to pa-
tients who received liver transplantation (LT). METHODS: The COME Study was a
naturalistic, multicenter, retrospective (time horizon: 6 months) work involving
1088 adult patients with CHDs. Costs were assessed from the societal perspective
and are reported as mean /patient-month (direct costs) and mean days lost from
work/study/usual activities per patient-month (loss of productivity). Patients’
Health Related Quality of Life was assessed with the EQ-5D questionnaire and is
reported as percentage of patientswith problems and asmeanSD visual analogue
scale (VAS) score. RESULTS: A total of 11.8% of the study sample had a LT. These
patients were 72.9% male, aged 19-72 (median57.5) years. Etiological agents re-
sponsible for LT were: HBV (36.2%), HCV (43.1%), HBV-HCV co-infection (3.4%),
other etiology (17.3%). Mean direct cost were 2628.8 €/patient-month. Hospitaliza-
tions contributed to 56.4% of costs, 40.2% generated from 11 patients who received
LT during the observational period. Treatment contributed to 39.5% of costs. Out-
patient contributed to 0.3% of costs. Nonmedical costs contributed to 3.7% of direct
costs. Three days/patient-month of productivity was lost by the patients and their
family caregivers. Thirty-four percent of patients reported problems in walking
about, 12.4% had problems with self-care, 42.1% had problems in doing usual ac-
tivities, 49.2% had pain or discomfort, and 40.2% had anxiety or depression. The
meanSD VAS was 69.120.5. CONCLUSIONS: High societal costs are generated
from having CHDs and in particular among patients with LT. The implementation
of efficient treatments aimed to reduce worsening of CHDs can help to improve
patients’ health and reduce societal costs.
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OBJECTIVES: The burden of Chronic Hepatic Diseases’ (CHDs) is little known. We
aimed to assess costs (direct, indirect and intangible) in patients with CHDs. The
following results pertain to patients with chronic Hepatitis C (HC).METHODS:We
conducted a naturalistic, multicenter, retrospective Cost-of-Illness study, named
COME. Costs occurring during the 6months before enrollment were assessed from
the societal perspective (i.e., NHS, patients and caregivers). Direct costs included
non medical (traveling/accommodation, formal caregiver payments) and medical
costs: conventional drug and unconventional treatment (e.g., homeopathy, herbal
medicines, vitamins, etc), hospitalization, outpatient medical visits and diagnostic
examinations. Loss of productivity was measured for patients and caregivers. Re-
sults are expressed as: €/patient-month (direct costs); days/patient-month (indi-
rect cost). Patients’ HRQoL was assessed with the EQ-5D questionnaire and is re-
ported as percentage of patients with problems and as meanSD visual analogue
scale (VAS) score. RESULTS:A total of 31.8% of the study sample (1088 patients) had
chronic HC. These patients were 54.6% male, aged 20-83 (median60.2) years.
Overall HC patients generatedmean direct costs corresponding to 233,68€/patient-
month. Treatment contributed to 71.1% of costs. Ribavirin-INF protocol was ad-
opted in 57.7% of patients. Hospitalizations contributed to 14.7% of costs and in-
volved 11.6% of the patients. Outpatient accesses contributed to 7.4% of costs and
involved 98% of the patients. Non medical costs contributed to 6.8% of direct costs
and involved 92.1% of the patients. Patients and their family caregivers lost on
average 0.7 days/patient-month of productivity. Twenty percent of patients re-
ported problems in walking about, 12.5% had problems with self-care, 25.4% had
problems in doing usual activities, 36.3% had pain/discomfort, and 44.7% had anx-
iety/depression. The meanSD VAS was 68.820.3. CONCLUSIONS: Chronic HC
generates high costs to the health care system. The use of efficient treatments is
necessary to reduce worsening of patients’ health, direct and indirect costs.
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OBJECTIVES: The burden of Chronic Hepatic Diseases (CHDs) is little known. We
aimed to assess social burden (direct, indirect and intangible cost) in patients with
CHDs. The following results pertain to patients with chronic Hepatitis B (HB).
METHODS: COME is a naturalistic, multicenter, retrospective cost of illness study.
Costs occurring during the 6 months before enrollment were assessed from the
societal perspective. Direct costs included nonmedical (traveling/accommodation,
caregiver payments) and medical costs: conventional (drug) and unconventional
treatment (e.g., homeopathy, vitamins, etc), hospitalization, outpatient medical
visits and diagnostic examinations. Loss of productivity wasmeasured for patients
and caregivers. Results are expressed as: €/patient-month (direct costs); days/pa-
tient-month (indirect costs). Patients’ HRQoL was assessed with the EQ-5D ques-
tionnaire and is reported as percentage of patientswith problems and asmeanSD
VAS score. RESULTS: Among 1088 adult patients enrolled, 221 had chronic HB
(20.3%). These patients were 69.7% male, aged 19-81(median56.1) years. Overall
HB patients generated mean direct costs corresponding to 308.1€/patient-month.
Treatment contributed to 76.9% of costs, involving 53.4% of the patients. In partic-
ular, 46.2% of patients were treated with antiviral drugs for systemic use (lamivu-
dine, ribavirin, etc). Hospitalizations contributed to 12.9% of costs and involved
9.0% of the patients. Outpatient accesses contributed to 5.4% of costs and involved
99.1% of the patients. Non medical costs contributed to 4.8% of direct costs and
involved 90.8% of the patients. Patients and their family caregivers lost on average
0.4 days/patient-month of productivity. As regardsHRQoL, patients reporting prob-
lems were: 24.4% of patients in walking about, 12.0% in self-care, 30.5% in usual
activities, 36.1% in pain/discomfort and 45.6% in anxiety/depression domain. The
meanSD VAS was 71.2520.72. CONCLUSIONS: Chronic HB generates high costs
to the healthcare system. The use of efficient treatments is necessary to reduce
worsening of patients’ health, direct and indirect costs.
PGI20
PRE- TO POST-DIAGNOSIS INCREASE IN UTILIZATION AND COSTS OF
CHRONIC-USE MEDICATIONS AND OTHER MEDICAL RESOURCES IN MANAGED
CARE ENROLLEES WITH DIVERTICULITIS
Davis KL1, Yen L2, Loftus EV3, Hodgkins P2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Shire Development, LLC, Wayne, PA,
USA, 3Mayo Clinic, Rochester , MN, USA
OBJECTIVES:We assessed changes in utilization of common chronic-use medica-
tions and generalized all-causemedical services and costs pre- to post-diagnosis in
a real-world diverticulitis (DV) population.METHODS: Insurance claims from 40
US health plans representing 50 million lives were retrospectively analyzed. In-
clusion criteria were: primary diagnosis of colonic DV (ICD-9 562.11, 562.13) be-
tween January 1, 2005 and December 31, 2008; antibiotic within 3 days post-diag-
nosis; 12 months pre- and post-diagnosis enrollment. Use of non-GI-related
medications, as well as overall all-cause utilization and costs (2009 US$), were
descriptively evaluated pre- to post-diagnosis. All-cause costs were also evaluated
for non-DV controls matched 2:1 on age, gender, and plan enrollment, with index
date assigned as diagnosis date of each respective DV match. RESULTS: A total of
25,172 patients met all inclusion criteria (51.2% male, mean age 53 years). The top
5 most prevalent chronic-use medications during pre-index were antihyperlipi-
demics (30.0% of patients), antihypertensives (27.5%), antidepressants (20.9%), der-
matologicals (20.0%) and beta blockers (15.7%). Post-index use of thesemedications
increased by 8.9%, 8.2%, 7.3%, 9.1%, and 11.7%, respectively (all P0.010). Mean
all-cause hospital days and costs per patient increased significantly pre- to post-
index (0.9 vs. 2.3 days, $3223 vs. $6341; all P0.010). Other significant (P0.010)
increases pre- to post-index were seen for ER visits (0.7 vs. 1.2; $432 vs. $1012),
prescriptions (22 vs. 27 fills, $1910 vs. $2081), office visits (10 vs. 12, $1747 vs. $2251),
and other outpatient/specialty consultations (3 vs. 5, $2676 vs. $4288) (all P0.010).
Total all-cause costs increased by 60%post-diagnosis ($10,419 vs. $16,672; P0.010).
Minimal change occurred for controls ($6299 vs. $6493; P0.010). CONCLUSIONS:
Patients with DV have higher use of common chronic-use prescriptions after diag-
nosis, as well as significantly higher use and costs of general all-cause medical
services. Payers should be aware of increased costs for not only disease-related
services, but also other general health care.
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OBJECTIVES: Clostridium difficile-associated disease (CDAD) is a nosocomial gas-
trointestinal infection that has been associated with increases in health care costs.
Fidaxomixin was recently approved for CDAD but is costly compared to conven-
tional agents. We evaluated the cost-effectiveness of fidaxomicin, metronidazole,
and vancomycin in the treatment of CDAD.METHODS: A decision analysis model
was created to estimate the cost-effectiveness of fidaxomicin, metronidazole, and
vancomycin in clinical cure from the US health care payer perspective. Parameters
for the model were determined from the published literature and indirect treat-
ment comparison was performed using Bayesian methods to obtain the probabil-
ities for responder and recurrence rates. Medication costs were determined from
the AWP and resource costs were determined fromCPT and HCPCS codes. All costs
were adjusted for 2011 US dollars. Probabilities of responder and recurrence, costs,
and resource utilization were fitted with a beta, gamma, and triangle distribution,
respectively. Probabilistic sensitivity analysis with 10,000 trial simulations was
performed to test the robustness of the model. Probabilities of cost-effectiveness
for different treatment strategieswere plotted on a cost-effectiveness acceptability
frontier (CEAF). RESULTS: The total direct costs for fidaxomicin, metronidazole,
and vancomycin were $14,219.98, $13,927.53, and $13,554.08, respectively. The
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